Bayview Legacy trims Arteris (AIP) stake with 2,116-share planned sale
Rhea-AI Filing Summary
Bayview Legacy, LLC, a 10% owner of Arteris, Inc. (AIP), reported an open-market sale of 2,116 shares of Arteris common stock on January 13, 2026. The shares were sold at a weighted average price of $17.7901 per share, in multiple trades between $17.7500 and $17.8100. The transaction was made under a Rule 10b5-1 trading plan adopted on March 5, 2025, meaning the sales followed a pre-set schedule. After this sale, Bayview Legacy, LLC indirectly beneficially owned 9,416,955 shares, and its manager, K. Charles Janac, is deemed to have voting and dispositive power over those shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 2,116 | $17.7901 | $38K |
Footnotes (1)
- Transaction made pursuant to a 10b5-1 trading plan that was adopted by the Reporting Person on March 5, 2025. K. Charles Janac, in his individual capacity, has separately filed a Form 4 on the date hereof reporting the same transaction given his beneficial ownership of the reported security through Bayview Legacy, LLC, which he controls as its manager. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.7500 to $17.8100 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. K. Charles Janac is the manager of Bayview Legacy, LLC and as such is deemed to have voting and dispositive power over the shares beneficially owned by Bayview Legacy, LLC.
FAQ
Who reported this insider transaction for Arteris (AIP)?
The transaction was reported by Bayview Legacy, LLC, which is identified as a 10% owner of Arteris, Inc..
Was this Arteris (AIP) insider sale under a Rule 10b5-1 plan?
Yes. The sale was made pursuant to a Rule 10b5-1 trading plan that was adopted by the reporting person on March 5, 2025.